CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于新抗原的 TCR-T 疗法在实体瘤中的应用
英文原题：Neoantigen-based TCR-T therapy in solid tumors.
查看英文原题
Neoantigen-based TCR-T therapy in solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞免疫疗法是一种颇具吸引力的癌症免疫疗法，主要包括基于嵌合抗原受体（CARs）的修饰T细胞和工程化T细胞受体（TCRs）。在实体瘤治疗方面，TCR-T细胞相较于CAR-T 具有显著优势，能够识别表达于细胞表面和细胞内的抗原，并且由于TCR具有正常的生理性T细胞激活结构，其不良反应风险更低。本研究旨在概述新型TCR相关癌症治疗靶点，以拓展TCR-T细胞疗法的应用，重点关注在患者中鉴定新型抗原和新型TCR的方法，并讨论TCR-T当前面临的主要挑战，描述提高其安全性和疗效的潜在解决方案。最后，我们讨论上述研究的最新临床研究现状，为促进TCR-T未来的进一步发展提供新思路。
展开英文摘要原文
T-cell immunotherapy is an appealing cancer immunotherapy that consists mainly of modified T cells based on chimeric antigen receptors (CARs) and engineered T-cell receptors (TCRs). TCR-T cells have significant advantages over CAR-T for solid tumor treatment, with the ability to recognize antigens expressed on the cell surface and in the intracellular compartment, and have a lower risk of adverse effects due to the normal physiological T cell activation architecture of the TCR.
This study aims to provide an overview of novel TCR-related cancer therapeutic targets to expand the application of TCR-T cell therapy, focusing on methods to identify novel antigens in patients and novel TCRs, and discusses the main current challenges of TCR-T, describing potential solutions to improve its safety and efficacy.
Finally, we discuss the latest clinical research status of its above studies, providing new ideas to promote further development of TCR-T in the future.
论文信息
- 作者
- Feng W、Wu D、Li Y
- 第一作者单位
- Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan, P.R. China.China
- 通讯作者单位
- Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan, P.R. China. Electronic address: yukun_li@csu.edu.cn.China
- 文献类型
- 综述
- 期刊
- International review of cell and molecular biology2026
- 原文标识
- PubMed 42191272 · DOI 10.1016/bs.ircmb.2025.11.001